Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 31

1.

Intense Uptake of Liposomal Curcumin by Multiple Myeloma Cell Lines: Comparison to Normal Lymphocytes, Red Blood Cells and Chronic Lymphocytic Leukemia Cells.

Bolger GT, Licollari A, Bagshaw R, Tan A, Greil R, Vcelar B, Majeed M, Sordillo P.

Anticancer Res. 2019 Mar;39(3):1161-1168. doi: 10.21873/anticanres.13225.

PMID:
30842145
2.

Pharmacokinetics of liposomal curcumin (Lipocurc™) infusion: effect of co-medication in cancer patients and comparison with healthy individuals.

Bolger GT, Licollari A, Tan A, Greil R, Vcelar B, Greil-Ressler S, Weiss L, Schönlieb C, Magnes T, Radl B, Majeed M, Sordillo PP.

Cancer Chemother Pharmacol. 2019 Feb;83(2):265-275. doi: 10.1007/s00280-018-3730-5. Epub 2018 Nov 14.

PMID:
30430227
3.

A phase 1 dose-escalation study on the safety, tolerability and activity of liposomal curcumin (Lipocurc) in patients with locally advanced or metastatic cancer.

Greil R, Greil-Ressler S, Weiss L, Schönlieb C, Magnes T, Radl B, Bolger GT, Vcelar B, Sordillo PP.

Cancer Chemother Pharmacol. 2018 Oct;82(4):695-706. doi: 10.1007/s00280-018-3654-0. Epub 2018 Aug 3.

4.

Distribution of Curcumin and THC in Peripheral Blood Mononuclear Cells Isolated from Healthy Individuals and Patients with Chronic Lymphocytic Leukemia.

Bolger GT, Licollari A, Tan A, Greil R, Pleyer L, Vcelar B, Majeed M, Sordillo P.

Anticancer Res. 2018 Jan;38(1):121-130.

PMID:
29277764
5.

Distribution and Metabolism of Lipocurc™ (Liposomal Curcumin) in Dog and Human Blood Cells: Species Selectivity and Pharmacokinetic Relevance.

Bolger GT, Licollari A, Tan A, Greil R, Vcelar B, Majeed M, Helson L.

Anticancer Res. 2017 Jul;37(7):3483-3492.

PMID:
28668837
6.

In Vitro Study of a Liposomal Curcumin Formulation (Lipocurc™): Toxicity and Biological Activity in Synovial Fibroblasts and Macrophages.

Kloesch B, Gober L, Loebsch S, Vcelar B, Helson L, Steiner G.

In Vivo. 2016 Jul-Aug;30(4):413-9.

PMID:
27381602
7.

Erythropoietin preconditioning improves clinical and histologic outcome in an acute spinal cord ischemia and reperfusion rabbit model.

Simon FH, Erhart P, Vcelar B, Scheuerle A, Schelzig H, Oberhuber A.

J Vasc Surg. 2016 Dec;64(6):1797-1804. doi: 10.1016/j.jvs.2015.10.011. Epub 2015 Nov 21.

8.

Regulatory approval and a first-in-human phase I clinical trial of a monoclonal antibody produced in transgenic tobacco plants.

Ma JK, Drossard J, Lewis D, Altmann F, Boyle J, Christou P, Cole T, Dale P, van Dolleweerd CJ, Isitt V, Katinger D, Lobedan M, Mertens H, Paul MJ, Rademacher T, Sack M, Hundleby PA, Stiegler G, Stoger E, Twyman RM, Vcelar B, Fischer R.

Plant Biotechnol J. 2015 Oct;13(8):1106-20. doi: 10.1111/pbi.12416. Epub 2015 Jul 3.

9.

Comparison of pharmacokinetic and safety profiles between Bemfola(®) and Gonal-f(®) after subcutaneous application.

Wolzt M, Gouya G, Sator M, Hemetsberger T, Irps C, Rettenbacher M, Vcelar B.

Eur J Drug Metab Pharmacokinet. 2016 Jun;41(3):259-65. doi: 10.1007/s13318-015-0257-6. Epub 2015 Jan 30.

10.

MABGEL 1: first phase 1 trial of the anti-HIV-1 monoclonal antibodies 2F5, 4E10 and 2G12 as a vaginal microbicide.

Morris GC, Wiggins RC, Woodhall SC, Bland JM, Taylor CR, Jespers V, Vcelar BA, Lacey CJ.

PLoS One. 2014 Dec 29;9(12):e116153. doi: 10.1371/journal.pone.0116153. eCollection 2014.

11.

Safety, tolerability and pharmacokinetics of liposomal curcumin in healthy humans.

Storka A, Vcelar B, Klickovic U, Gouya G, Weisshaar S, Aschauer S, Bolger G, Helson L, Wolzt M.

Int J Clin Pharmacol Ther. 2015 Jan;53(1):54-65. doi: 10.5414/CP202076.

PMID:
25500488
12.

Effect of liposomal curcumin on red blood cells in vitro.

Storka A, Vcelar B, Klickovic U, Gouya G, Weisshaar S, Aschauer S, Helson L, Wolzt M.

Anticancer Res. 2013 Sep;33(9):3629-34.

PMID:
24023289
13.

Protective effect of vaginal application of neutralizing and nonneutralizing inhibitory antibodies against vaginal SHIV challenge in macaques.

Moog C, Dereuddre-Bosquet N, Teillaud JL, Biedma ME, Holl V, Van Ham G, Heyndrickx L, Van Dorsselaer A, Katinger D, Vcelar B, Zolla-Pazner S, Mangeot I, Kelly C, Shattock RJ, Le Grand R.

Mucosal Immunol. 2014 Jan;7(1):46-56. doi: 10.1038/mi.2013.23. Epub 2013 Apr 17.

PMID:
23591718
14.

The neuroprotective and neurorescue effects of carbamylated erythropoietin Fc fusion protein (CEPO-Fc) in a rat model of Parkinson's disease.

Thomas Tayra J, Kameda M, Yasuhara T, Agari T, Kadota T, Wang F, Kikuchi Y, Liang H, Shinko A, Wakamori T, Vcelar B, Weik R, Date I.

Brain Res. 2013 Mar 28;1502:55-70. doi: 10.1016/j.brainres.2013.01.042. Epub 2013 Feb 1.

15.

Carbamylated erythropoietin-FC fusion protein and recombinant human erythropoietin during porcine kidney ischemia/reperfusion injury.

Matějková Š, Scheuerle A, Wagner F, McCook O, Matallo J, Gröger M, Seifritz A, Stahl B, Vcelar B, Calzia E, Georgieff M, Möller P, Schelzig H, Radermacher P, Simon F.

Intensive Care Med. 2013 Mar;39(3):497-510. doi: 10.1007/s00134-012-2766-y. Epub 2013 Jan 5.

PMID:
23291730
16.

Infusion pharmacokinetics of Lipocurc™ (liposomal curcumin) and its metabolite tetrahydrocurcumin in Beagle dogs.

Helson L, Bolger G, Majeed M, Vcelar B, Pucaj K, Matabudul D.

Anticancer Res. 2012 Oct;32(10):4365-70.

PMID:
23060560
17.

Tissue distribution of (Lipocurc™) liposomal curcumin and tetrahydrocurcumin following two- and eight-hour infusions in Beagle dogs.

Matabudul D, Pucaj K, Bolger G, Vcelar B, Majeed M, Helson L.

Anticancer Res. 2012 Oct;32(10):4359-64.

PMID:
23060559
18.

Human pharmacokinetics of intravenous recombinant human Cu/Zn superoxide dismutase.

Schaller G, Dittrich P, Felizeter M, Gouya G, Leuchten N, Kapiotis S, Vcelar B, Vorauer-Uhl K, Wolzt M.

Int J Clin Pharmacol Ther. 2012 Jun;50(6):413-7. doi: 10.5414/CP201651.

PMID:
22541746
19.

The effect of erythropoietin on platelet and endothelial activation markers: a prospective trial in healthy volunteers.

Heinisch BB, Vcelar B, Kapiotis S, Blann A, Wolzt M, Siller-Matula JM, Jilma B.

Platelets. 2012;23(5):352-8. doi: 10.3109/09537104.2011.631621. Epub 2011 Nov 18.

PMID:
22098110
20.

Comparison of carbamylated erythropoietin-FC fusion protein and recombinant human erythropoietin during porcine aortic balloon occlusion-induced spinal cord ischemia/reperfusion injury.

Simon F, Scheuerle A, Gröger M, Vcelar B, McCook O, Möller P, Georgieff M, Calzia E, Radermacher P, Schelzig H.

Intensive Care Med. 2011 Sep;37(9):1525-33. doi: 10.1007/s00134-011-2303-4. Epub 2011 Jul 16.

PMID:
21779851
21.

Reassessment of autoreactivity of the broadly neutralizing HIV antibodies 4E10 and 2F5 and retrospective analysis of clinical safety data.

Vcelar B, Stiegler G, Wolf HM, Muntean W, Leschnik B, Mehandru S, Markowitz M, Armbruster C, Kunert R, Eibl MM, Katinger H.

AIDS. 2007 Oct 18;21(16):2161-70.

PMID:
18090042
22.

Adjunctive passive immunotherapy in human immunodeficiency virus type 1-infected individuals treated with antiviral therapy during acute and early infection.

Mehandru S, Vcelar B, Wrin T, Stiegler G, Joos B, Mohri H, Boden D, Galovich J, Tenner-Racz K, Racz P, Carrington M, Petropoulos C, Katinger H, Markowitz M.

J Virol. 2007 Oct;81(20):11016-31. Epub 2007 Aug 8.

23.

Long-term multiple-dose pharmacokinetics of human monoclonal antibodies (MAbs) against human immunodeficiency virus type 1 envelope gp120 (MAb 2G12) and gp41 (MAbs 4E10 and 2F5).

Joos B, Trkola A, Kuster H, Aceto L, Fischer M, Stiegler G, Armbruster C, Vcelar B, Katinger H, Günthard HF.

Antimicrob Agents Chemother. 2006 May;50(5):1773-9.

24.

Liposomal recombinant human superoxide dismutase for the treatment of Peyronie's disease: a randomized placebo-controlled double-blind prospective clinical study.

Riedl CR, Sternig P, Gallé G, Langmann F, Vcelar B, Vorauer K, Wagner A, Katinger H, Pflüger H.

Eur Urol. 2005 Oct;48(4):656-61.

PMID:
15982798
25.

Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies.

Trkola A, Kuster H, Rusert P, Joos B, Fischer M, Leemann C, Manrique A, Huber M, Rehr M, Oxenius A, Weber R, Stiegler G, Vcelar B, Katinger H, Aceto L, Günthard HF.

Nat Med. 2005 Jun;11(6):615-22. Epub 2005 May 8.

PMID:
15880120
26.

Neutralization profiles of newly transmitted human immunodeficiency virus type 1 by monoclonal antibodies 2G12, 2F5, and 4E10.

Mehandru S, Wrin T, Galovich J, Stiegler G, Vcelar B, Hurley A, Hogan C, Vasan S, Katinger H, Petropoulos CJ, Markowitz M.

J Virol. 2004 Dec;78(24):14039-42.

27.

Passive immunization with the anti-HIV-1 human monoclonal antibody (hMAb) 4E10 and the hMAb combination 4E10/2F5/2G12.

Armbruster C, Stiegler GM, Vcelar BA, Jäger W, Köller U, Jilch R, Ammann CG, Pruenster M, Stoiber H, Katinger HW.

J Antimicrob Chemother. 2004 Nov;54(5):915-20. Epub 2004 Sep 29.

PMID:
15456731
28.

Live cold-adapted influenza A vaccine produced in Vero cell line.

Romanova J, Katinger D, Ferko B, Vcelar B, Sereinig S, Kuznetsov O, Stukova M, Erofeeva M, Kiselev O, Katinger H, Egorov A.

Virus Res. 2004 Jul;103(1-2):187-93.

PMID:
15163508
29.

Antiviral activity of the neutralizing antibodies 2F5 and 2G12 in asymptomatic HIV-1-infected humans: a phase I evaluation.

Stiegler G, Armbruster C, Vcelar B, Stoiber H, Kunert R, Michael NL, Jagodzinski LL, Ammann C, Jäger W, Jacobson J, Vetter N, Katinger H.

AIDS. 2002 Oct 18;16(15):2019-25.

PMID:
12370500
30.

A phase I trial with two human monoclonal antibodies (hMAb 2F5, 2G12) against HIV-1.

Armbruster C, Stiegler GM, Vcelar BA, Jäger W, Michael NL, Vetter N, Katinger HW.

AIDS. 2002 Jan 25;16(2):227-33.

PMID:
11807307
31.

Pilot study on liposomal recombinant human superoxide dismutase for the treatment of Peyronie's disease.

Riedl CR, Plas E, Vorauer K, Vcelar B, Wagner A, Pflüger H.

Eur Urol. 2001 Sep;40(3):343-8; discussion 348-9. Review.

PMID:
11684853

Supplemental Content

Loading ...
Support Center